Aug 20 2026 10:46 PM EST

Amylyx Surges on Clinical Data; Alpha Metallurgical Gains on Insider Activity as F&G Slides on Earnings and Leadership Uncertainty

Amylyx Pharmaceuticals (NASDAQ: AMLX) led the market’s top performers over the past five trading days, with its shares soaring by 50.4% after pivotal late-stage clinical trial results for avexitide. Alpha Metallurgical Resources (NYSE: AMR) also posted a strong gain of 24.9% as insider buying and sector-wide momentum in metallurgical coal offset persistent cost headwinds. At the other end of the spectrum, F&G Annuities & Life (NYSE: FG) shares declined by 3.90%, extending a 25.12% year-to-date slide, after reporting weaker-than-expected alternative investment returns and navigating a major leadership transition.

Biotech Leads on Clinical Catalyst

Amylyx Pharmaceuticals’ rally was driven by the release of positive Phase 3 LUCIDITY trial data for avexitide, a GLP-1 receptor antagonist targeting post-bariatric hypoglycemia (PBH). The study showed a 55% reduction in severe hypoglycemic events versus placebo (p=0.000003), with avexitide meeting all secondary endpoints and exhibiting a favorable safety profile. The data reinforced market confidence that Amylyx could deliver the first FDA-approved therapy for PBH, a condition affecting an estimated 160,000 Americans post-bariatric surgery.

The news triggered a surge in trading volume—over 24 million shares, nearly 12x the average—and Amylyx’s stock closed at $35.11 on August 18, up from $21.43 the previous session. The company’s strategic pivot to avexitide, following the withdrawal of its ALS drug RELYVRIO in 2024, has transformed its outlook. With $250.8 million in cash at the end of the second quarter and an additional $350 million equity raise, Amylyx is positioned to fund operations into 2028 as it prepares for a planned FDA submission and potential commercial launch in 2027.

Analyst price targets now range from $26 to $40, with the stock trading 349.0% above year-ago levels. The magnitude and specificity of the clinical data, coupled with a clear regulatory path and strong institutional support, set Amylyx apart from a sector where few small-cap biotechs have delivered late-stage success in 2026.

Insider Activity and Sector Tailwinds Lift Alpha Metallurgical

Alpha Metallurgical Resources’ shares advanced on a combination of insider confidence and sector-wide coal market dynamics. The company disclosed a director’s purchase of 10,000 shares for $2.0 million in June, alongside ongoing share repurchases that reduced shares outstanding by 1.44% year over year and 41% since 2022. This activity was interpreted as a signal of management’s confidence, helping the stock rise to $194.30 despite reporting a second-quarter net loss of $12.3 million and revenue down 10.4% year over year to $421.29 million.

Alpha’s operational challenges included storm-related shipment disruptions and rising mining costs, prompting management to lower 2026 shipment guidance to 14.2–15.4 million tons and raise per-ton cost guidance to $103–$107. However, global supply disruptions and rising U.S. export volumes have supported robust pricing—global coking coal averaged $267.88 per metric ton in the second quarter, up 4.2% sequentially. With $447.8 million in liquidity and no debt, Alpha remains well positioned to continue its buyback program and weather commodity volatility.

While analysts maintain Hold or Reduce ratings with price targets between $165–$194, sector-wide momentum and Alpha’s capital allocation strategy have underpinned recent gains. The company’s high exposure to export markets (78% of 2024 revenues) positions it to benefit from ongoing supply chain disruptions, despite headwinds from cost inflation and operational bottlenecks.

F&G Slides on Earnings and Strategic Uncertainty

F&G Annuities & Life’s underperformance followed a second-quarter report marked by weak alternative investment returns, continued earnings pressure and significant leadership changes. Adjusted net earnings fell to $85 million ($0.65 per share), down from $103 million ($0.77 per share) a year earlier. Net loss attributable to common shareholders was $(81) million, reversing a prior-year profit, with alternative investment returns dropping to $49 million and annualized yields well below management’s long-term target.

The retirement of CEO Chris Blunt and the appointment of Conor Murphy as his successor, along with a new CFO, have added to strategic uncertainty. F&G is conducting a review of its distribution business and aims to pivot to a more fee-based, capital-light model, with a goal of 25% fee-based earnings by 2028. However, near-term results have yet to reflect any benefit from this strategy, and adjusted return on equity (ex-AOCI) declined to 8.0%, lagging sector peers.

Broader sector headwinds—including volatile interest rates, inflation, and heightened regulatory scrutiny—are compounding F&G’s challenges. The shares now trade at a forward P/E of 6.49 and a price-to-book ratio of 0.78, below insurance sector averages, with consensus ratings at Hold and a $27 12-month price target. The principal risks remain earnings volatility, compressed spreads, and uncertainty surrounding capital and regulatory requirements.

Investor Positioning and Key Catalysts Ahead

The past week’s stock moves highlight investors’ willingness to reward clear, company-specific catalysts and disciplined capital allocation, even amid persistent sector headwinds. Amylyx’s outperformance underscores the premium attached to late-stage clinical success and first-mover product potential within a challenging biotech landscape. In contrast, Alpha Metallurgical’s gains reflect the continued appeal of shareholder-friendly capital returns and sector tailwinds, despite operational risks and lackluster earnings. F&G’s decline illustrates the market’s skepticism toward insurance models exposed to volatile alternative investments and ongoing management transitions.

Looking ahead, the sustainability of these moves will hinge on the ability of Amylyx to secure regulatory approval and execute its commercial launch, Alpha Metallurgical’s management of costs and export opportunities, and F&G’s progress in stabilizing earnings and articulating a credible strategic path. For investors, the current environment favors companies with visible catalysts, operational discipline and resilient balance sheets as macro and regulatory uncertainty persists.